Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pharmacodynamic study of bevacizumab and pazopanib in metastatic renal cell carcinoma
2008-005053-38Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab and pazopanib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by GSK. Primary endpoints: Primary pharmacodynamic endpoints for bevacizumab (Part I) and Comparison of pharmacodynamic effects of bevacizumab vs pazopanib. Started Apr 2009; status: completed.
02
Drugs
bevacizumabpazopanib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2008-005053-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005053-38.